Sökning: "crizotinib"

Visar resultat 1 - 5 av 9 avhandlingar innehållade ordet crizotinib.

1. 1. Anaplastic lymphoma kinase activity, a therapeutic target, suppresses neuroblastoma cell differentiation

   Författare :Joachim T. Siaw; Göteborgs universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Neuroblastoma; ALK; 11q.; DLG2; SP1; differentiation; crizotinib; ceritinib; brigatinib;

   Sammanfattning : Neuroblastoma (NB) is the most common extracranial pediatric solid malignancy caused by the failed differentiation of precursor cells of the developing sympathetic nervous system. NB accounts for about 15% of childhood cancer-related deaths. LÄS MER

3. 2. Mechanistic Implications and Characterization of Anaplastic Lymphoma Kinase (ALK) mutations in Neuroblastoma

   Författare :Damini Chand; Bengt Hallberg; Christer Larsson; Umeå universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; neuroblastoma; ALK; crizotinib; receptor tyrosine kinase; molekylärbiologi; Molecular Biology;

   Sammanfattning : Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that was first reported as a fusion partner of nucleophosmin in Anaplastic large cell lymphoma in 1994. ALK is involved in myriad of cancers including neuroblastoma which is the most common extracranial solid tumor affecting young children. LÄS MER

4. 3. Anaplastic Lymphoma Kinase mutations and downstream signalling

   Författare :Christina Schönherr; Ruth H Palmer; Aristidis Moustakas; Umeå universitet; []
   Nyckelord :NATURVETENSKAP; NATURAL SCIENCES; Anaplastic Lymphoma Kinase; oncogene; RTK; neuroblastoma; crizotinib; NVP-TAE684; gain-of-function; MYCN; transcription factor; small GTPase; Rap1; C3G; PC12 cells; neurite outgrowth; molecular cell biology; molekylär cellbiologi;

   Sammanfattning : The oncogene Anaplastic Lymphoma Kinase (ALK) is a Receptor Tyrosine Kinase (RTK) and was initially discovered as the fusion protein NPM (nucleophosmin)-ALK in a subset of Anaplastic Large Cell Lymphomas (ALCL). Since then more fusion proteins have been identified in a variety of cancers. LÄS MER

5. 4. Investigating ALK inhibitors alone or in combination as therapeutic options for ALK-positive neuroblastoma

   Författare :Muhammad Wasi Alam; Göteborgs universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Neuroblastoma; Oncology; Anaplastic lymphoma kinase ALK ; Dihydroorotate Dehydrogenase DHODH ;

   Sammanfattning : Neuroblastoma (NBL) is the third most common pediatric cancer after leukemia and cranial tumours and accounts for around 15% of death in pediatric malignancy. NBL develops due to the poorly differentiated progenitor cells of the sympathetic nervous system. LÄS MER

7. 5. Hitting the right targets : a study of molecular mediators of sensitivity to novel potential targeted therapies in cutaneous malignant melanoma

   Författare :Ishani Das; Karolinska Institutet; Karolinska Institutet; []
   Nyckelord :;

   Sammanfattning : Cutaneous malignant melanoma (CMM) is the deadliest form of skin cancer with a 5-year overall survival (OS) rate of less than 10% among patients diagnosed with disseminated disease. During the past decade the emergence and use of novel targeted therapy and immunotherapy has significantly increased the 5-year OS rate (34%). LÄS MER